66
Participants
Start Date
May 18, 2014
Primary Completion Date
February 14, 2018
Study Completion Date
February 14, 2018
Tepotinib
Participants received a single oral dose of Tepotinib 300 milligram (mg) in each 21 days treatment cycle until progressive disease, intolerable toxicity, death, or withdrawal from treatment.
Tepotinib
Participants received a single oral dose of Tepotinib 500 mg daily in each 21 days treatment cycle until progressive disease, intolerable toxicity, death, or withdrawal from treatment.
Please contact the Merck KGaA Communication Center located in, Darmstadt
Merck KGaA, Darmstadt, Germany
INDUSTRY